ABSTRACT
PURPOSE: To determine the efficacy of topical application and subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. METHODS: Corneal neovascularization was induced with a silk suture of the corneal stroma in 12 rabbits (24 eyes). One week after suturing, four rabbits were treated with topical bevacizumab at 5 mg/mL (group A) and another four rabbits were treated with topical bevacizumab 10 mg/mL (group B) in the right eyes twice a day for two weeks. A subconjunctival injection of bevacizumab 1.25 mg/mL was done in the right eyes of four rabbits (group C). All of the left eyes (12 eyes) were used as controls. The area of corneal neovascularization was measured after one and two weeks, and the concentration of vascular endothelial growth factor (VEGF) in corneal tissue was measured after two weeks. RESULTS: The neovascularized area was smaller in all treated groups than in the control group (p<0.001). Upon analysis of the neovascularized area, there was no significant difference between groups A and B. However, the mean neovascularized area of group B was significantly smaller than that of group C after two weeks of treatment (p=0.043). The histologic examination revealed fewer new corneal vessels in all treated groups than the control group. The concentration of VEGF was significantly lower in all treated groups compared to the control group (p<0.01), but no difference was shown between treated groups. CONCLUSIONS: Topical and subconjunctival bevacizumab application may be useful in the treatment of corneal neovascularization and further study is necessary.
Subject(s)
Animals , Female , Male , Rabbits , Angiogenesis Inhibitors/administration & dosage , Antibodies, Monoclonal/administration & dosage , Cornea/metabolism , Corneal Neovascularization/drug therapy , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Administration Schedule , Follow-Up Studies , Ophthalmic Solutions , Treatment Outcome , Vascular Endothelial Growth Factor A/antagonists & inhibitorsABSTRACT
PURPOSE: To investigate the postoperative results of Descemet's stripping automated endothelial keratoplasty in bullous keratoplasty and graft failure cases. CASE SUMMARY: Eight eyes of eight patients who underwent DSAEK between September 2006 and August 2008 were followed-up for at least 3 months, and the charts of eight patients were reviewed retrospectively. Five eyes of the total eight had bullous keratopathy, and three eyes needed DSAEK due to graft failure. The best corrective visual acuity (logMAR) improved from 1.625+/-0.60 to 0.825+/-0.35 and corneal thickness decreased from 785.63+/-135.58 microm to 692.00+/-150.85 microm 3 months postoperatively. Grafted corneal dislocation occurred in two eyes, and we repositioned the cornea in those participants by air injection. We found graft rejection signs in two cases, and one case showed graft failure despite steroid therapy. CONCLUSIONS: We think that DSAEK will be a good surgical procedure in bullous keratopathy or graft failure patients because of its favorable postoperative prognosis.
Subject(s)
Humans , Cornea , Corneal Transplantation , Joint Dislocations , Eye , Graft Rejection , Prognosis , Retrospective Studies , Transplants , Visual AcuityABSTRACT
PURPOSE: To investigate the results when using the acellular dermal allograft (SureDerm(R), Hans Biomed Co., Korea) as a new wrapping material for porous orbital implants. METHODS: The charts of 11 patients who underwent either primary or secondary insertion of Medpor(R) orbital implants after enucleation or a new insertion after removal of previous orbital implants were reviewed. Medpor(R) orbital implants either 18 or 20 mm were wrapped with SureDerm(R) in 4x4 cm sections that were 1-mm-thick. Four rectus muscles were fixed to the SureDerm(R) wrapped implant, and a conjunctival suture was made with 6-0 Vicryl. All patients had follow-up periods longer than 10 months and were evaluated to determine the success of wrapping and to identify any complications. RESULTS: The average age of the patients was 48.3 years. The patients wore artificial eyes for 9 weeks after the operation, and the follow-up periods were 22.4 months on average. There was no case of implant or SureDerm(R) exposure, inflammation, and other significant complications except in one case that required fornix reconstruction to allow the subject to wear an artificial eye. CONCLUSIONS: Acellular dermal allograft appears to be a good substitute material if preserved sclera is not available when inserting orbital implants with wrapping.